title: Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases.
abstract: Reversing inflammatory lung disease remains the foremost challenge in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease. Reducing (or modifying) the underlying inflammatory process with mono-target drugs has proven challenging. The era of designing 'one target for one disease' has evolved such that a growing body of evidence suggests a single drug that is capable of specifically targeting multiple targets and pathways would be better at arresting progression of these respiratory diseases and be an important advancement in current therapy. Oligonucleotide-based drugs represent an emerging class of drug candidates. Their properties, a broader range of targets over conventional small-molecule drugs and recent clinical proof-of-concept support their development as novel multi-targeting agents for the treatment of respiratory diseases.
authors.affiliation: Topigen Pharmaceuticals Inc., (Part of the Pharmaxis Ltd group) 2901 Rachel Street East, Suite 13, Montreal, QC, H1W 4A4, Canada. nicolay.ferrari@topigen.com
authors.forename: Nicolay
authors.initials: N
authors.lastname: Ferrari
authors.forename: Rosanne
authors.initials: R
authors.lastname: Seguin
authors.forename: Paolo
authors.initials: P
authors.lastname: Renzi
mesh_terms: D006801:Humans; D009841:Oligonucleotides / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000188:drug therapy*
chemical_list: D009841:Oligonucleotides